Raphael Itzykson, MD, PhD, Saint-Louis Hospital AP-HP, Paris, France, discusses the development of the niche-like ex vivo high throughput (NEXT) platform, a multiparametric drug sensitivity screening platform for primary acute myeloid leukemia (AML). The platform was validated in patients with NPM1 mutant AML treated with conventional daunorubicin plus cytarabine (DNR-AraC) chemotherapy. The results found that the NEXT assay could predict measurable residual disease (MRD) achievement in NPM1 mutant AML and identify novel sensitizers to DNA-AraC. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.